Drug search by name

Phenytoin Capsules and Renal dysfunction

Result of checking the interaction of drug Phenytoin Capsules and disease Renal dysfunction for safety when used together.

Check result:

Phenytoin Capsules <> Renal dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The plasma protein binding of phenytoin may be significantly decreased in patients with renal impairment, resulting in elevated free drug concentrations and increased risk of toxicity. This effect is proportional to the degree of renal impairment and stems from quantitative differences in serum albumin as well as qualitative differences in the ability to bind phenytoin. Therapy with phenytoin should be administered cautiously in patients with impaired renal function. Both the therapeutic and toxic plasma total phenytoin levels may be lower than normal in these patients and should be considered in dosing. Alternatively, the monitoring of unbound phenytoin concentrations may be appropriate.

References:

Browne TR, Kugler AR, Eldon MA "Pharmacology and pharmacokinetics of fosphenytoin." Neurology 46 (6 supp (1996): s3-7
"Product Information. Cerebyx (fosphenytoin)." Parke-Davis, Morris Plains, NJ.
Reidenberg MM, Odar-Cederlof I, Bahr C, von Borga O, Sjoqvist F "Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function." N Engl J Med 285 (1971): 264-7
Reidenberg MM "The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function." Am J Med 62 (1977): 466-70
Reynolds F, Jones NF, Ziroyanis PN, Smith SE "Salivary phenytoin concentrations in epilepsy and in chronic renal failure." Lancet 2 (1976): 384-9
Odar-Cederlof I, Borga O "Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding." Eur J Clin Pharmacol 7 (1974): 31-7
Tiula E, Haapanen EJ, Neuvonen PJ "Factors affecting serum protein binding of phenytoin, diazepam and propranolol in acute renal diseases." Int J Clin Pharmacol Ther Toxicol 25 (1987): 469-75
Mabuchi H, Nakahashi H "A major inhibitor of phenytoin binding to serum protein in uremia." Nephron 48 (1988): 310-4
"Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.
Tiula E, Neuvonen PJ "Effect of total drug concentration on the free fraction in uremic sera." Ther Drug Monit 8 (1986): 27-31
Hooper WD, Bochner F, Eadie MJ, Tyrer JH "Plasma protein binding of diphenylhydantoin: effects of sex hormones, renal and hepatic disease." Clin Pharmacol Ther 15 (1974): 276-82
Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S "Drug protein binding in chronic renal failure: evaluation of nine drugs." Kidney Int 33 (1988): 996-1004